Immunocompromised people may need COVID-19 vaccine booster shots: Experts
All people may not need a third dose or booster shot against COVID-19. India’s priority remains getting its adult population fully vaccinated with two doses.
Veeda Clinical Research files DRHP for Rs 831.6 crore IPO
The company intends to utilise the proceeds to repay debt, fund capital expenditure, invest in/fund further acquisitions by subsidiary Bioneeds and fund working capital requirements
Explainer: What is Ayushman Bharat Digital Mission, what this means to patients and concerns
The digital health ID, which creates a health account, will ensure that old medical records are not lost, as every record will be stored digitally. Though the govt says no medical practitioner will be able to access a citizen’s health data without his consent, there are concerns.
Bharat Biotech says working with WHO to obtain clearance, no word on approval delays
Bharat Biotech has said it doesn't 'find it appropriate to speculate or comment on the regulatory approval process and its timelines' after reports emerged of a possible delay in WHO approval
Biocon gets 6 observations from USFDA for its Malaysian facility in pre-approval inspection
"We are confident of addressing these observations through procedural enhancements and an appropriate Corrective and Preventive Action Plan (CAPA), which will be submitted to the US FDA in the stipulated time," Biocon spokesperson said.
Government’s free vaccination drive kills market for private hospitals, 25% allocation largely unutilised
With the wider availability of vaccines, people prefer to get their jabs at government centres rather than pay for shots at private hospitals.
Healthtech platform Medikabazaar raises $75 million from Creagis, CDC Group
The current investment will be utilized to strengthen Medikabazaar’s digital capabilities, deepen the supply ecosystem, technology driven distribution channels and bolster capacity to provide a wider range of leading-edge quality medical supplies across diverse geographical regions.
J&J says launch date of COVID-19 shots in India not decided, still in talks with govt
COVID-19 vaccines would be on the agenda of the Quad meeting scheduled on September 24 between the heads of the governments of the US, India, Japan and Australia, sources told Moneycontrol
Industry says UK’s non-recognition of Indian vaccine certificates ‘unfair’
India is the leading vaccine manufacturer for the world. Not recognising India's vaccine certificate is not acceptable, Dr Alok Roy, Chair of FICCI Health Services Committee, said. India’s digital certification is far more reliable than other countries’ manual systems, tweeted Kiran Mazumdar-Shaw, Chairperson of Biocon.
MSF asks Regeneron to make COVID antibody cocktail affordable; forego patent claims
Regenron has priced the antiviral cocktail at $820 (Rs 59,750) in India, $2,000 in Germany and $2,100 in the US. It has also filed patent applications in at least 11 low= and middle-income countries
Aurobindo Pharma's subsidiary seeks marketing approval of its first biosimilar product from EMA
Aurobindo Pharma is developing biosimilars for global markets through its subsidiary CuraTeQ Biologics with focus on oncology and immunology segments.
Lupin's Goa plant: USFDA finds certain investigation, material testing deficiencies
Lupin said the company is confident of addressing the observations satisfactorily
WHO panel to review Covaxin data for emergency-use listing on October 5
Inclusion of indigenously developed Covaxin in the WHO list will boost global acceptance of the Covid-19 vaccine.
UK to allow entry to travellers vaccinated with Covishield from October 4
Indians will still have to take tests on arrival and quarantine for ten days.
Explainer: Why India is relaxing export restrictions on COVID-19 vaccines
For one, India has to keep its commitment under a global initiative called COVAX. The other reason, as an expert says, is that if India doesn't ease export restrictions, it will benefit China, which is making deeper inroads into low and middle-income countries with vaccine diplomacy.
UK may review its new COVID travel policy for India: Sources
"Everybody knows that it is identical, it is been proven. We have submitted the data to EMA and the UK MHRA. They are reviewing it, I have had a personal consultation with the regulator there, they are going to get back to us shortly," said Adar Poonawalla, CEO of SII.
India to resume exports of surplus COVID-19 vaccines from October under Vaccine Maitri programme
Union health minister Mansukh Mandaviya said more than 30 crore doses will be produced in October and more than 100 crores in the coming quarter.
Adar Poonawalla-backed Mylab acquires point-of-care testing provider Sanskritech
Sanskritech's Swayam is a portable diagnostic and telemedicine point-of-care system that can be used to create a small lab anywhere. This will allow people to test for a wide range of diseases within a few minutes
Biocon, SII deal to extend to exploring partnership in biologics, mRNA vaccines
Biocon and SII are exploring development and commercialisation of SII's biologic portfolio, considering manufacture of raw materials for vaccines and biologics, and plan to develop and make drugs and vaccines based on mRNA platform.
Sputnik Light single-dose vaccine launch in India may get delayed
An expert panel of the Central Drugs Standard Control Organisation asks company to conduct Phase-3 immune-bridging clinical trials on Indian population. Dr Reddy's spokesperson declines to say when the trial will start.
Delayed launch of Glumetza: Lupin settles case for $248 million
The law suits in US courts alleged that the 2012 settlement of patent litigation regarding Glumetza delayed the availability of generic alternatives, causing consumers to pay higher prices for the drug.
DCGI led panel formed to frame new New Drugs, Cosmetics and Medical Devices Bill starts process
"The committee has decided to conduct a consultative meeting with the Consumer Associations scheduled to held on September 19 between 2 - 4 pm," the notification released by Somani said.
No new side effects found in COVID-19 antiviral Favipiravir: Glenmark
Glenmark said the time for fever resolution was four days while time for clinical cure was seven days.
Poonawalla-backed Wellness Forever to file for Rs 1,600-crore IPO
The retail pharmacy chain will file its draft documents by end-September.
- MC Explains | ONDC, the 'UPI of e-commerce' Watch more
- Can Tata Nexon EV Max Do Mumbai To Pune & Back In One Charge? Range Test On The Drive Report | Ep 1 Watch more
- Ideas For Profit | HDFC Life, SBI Life or ICICI Pru - which life insurance stock should you buy? Watch more
- Storyboard18 | Personalisation - Myths And Facts Watch more
- The Tenant | What makes Bandra tick for a tenant who is single? Watch more